Kimialys develops proprietary K-One® surface chemistry for the optimal immobilization of ligands on gold surfaces, enhancing the functionality of biosensors used in diagnostics and drug development. Their technology ensures over 90% of ligands remain functional, significantly improving sensitivity and specificity in detecting low concentrations of analytes while minimizing false positives.
Funding
Funding not disclosed
AFounders
Product
Problem
Conventional methods of ligand immobilization on gold surfaces often result in low functionality (typically below 30%) due to random binding, leading to reduced sensitivity and specificity in biosensor applications for diagnostics and drug development. This inefficiency hinders the accurate detection of low analyte concentrations and increases the occurrence of false positives, especially in complex biological samples.
Solution
Kimialys addresses this challenge with its proprietary K-One® surface chemistry, which enables optimal and covalent immobilization of ligands on gold surfaces, ensuring over 90% of ligands remain functional. This technology provides precise control over ligand exposure, orientation, density, and distribution, maximizing binding site accessibility and minimizing non-specific interactions. Kimialys offers tailored gold bioconjugates and SPR/SPRi services, enhancing the performance of biosensors used in in-vitro diagnostics and drug discovery. Their FirstTimeRight (FTR) approach tailors bioconjugation to specific biomolecules and assays, improving sensitivity, specificity, selectivity, and reproducibility without compromising any single parameter.
Target Audience
Kimialys serves developers of rapid and point-of-care tests, biotech and pharmaceutical companies engaged in drug discovery and development, and companies developing biosensors or assays.
Features
- K-One® surface chemistry for covalent and controlled ligand immobilization on gold nanoparticles, chips, and electrodes
- Tailored bioconjugation methodology (FTR) optimized for individual biomolecules and assays
- Up to 10x improvement in Limit of Detection (LoD) compared to standard methods in lateral flow assays
- Enhanced signal-to-noise ratio (SNR) in SPR/SPRi analysis
- Robust ligand attachment, ensuring stability through repeated analysis cycles
- Consultancy services for custom biosensor and assay development, including platform and biologics selection
- Multiplexed SPRi platform for 5x faster screening of antibodies